Literature DB >> 3344853

Carbamazepine in the treatment of catatonia.

H W Rankel1, L E Rankel.   

Abstract

Carbamazepine resolved within 6-24 hours the catatonic stupor in two patients, one with a schizophreniform and one with a schizoaffective disorder. Reports of frequent EEG abnormalities and the successful use of diazepam in catatonia prompted these trials with another anticonvulsant.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3344853     DOI： 10.1176/ajp.145.3.361

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  7 in total

1.  Organic catatonia: a review.

Authors:  N Ahuja
Journal:  Indian J Psychiatry       Date:  2000-10       Impact factor: 1.759

2.  Clinical manifestations, diagnosis, and empirical treatments for catatonia.

Authors:  Mahendra T Bhati; Catherine J Datto; John P O'Reardon
Journal:  Psychiatry (Edgmont)       Date:  2007-03

3.  Epileptic seizures in patients with acute catatonic syndrome.

Authors:  A Primavera; A Fonti; P Novello; G Roccatagliata; L Cocito
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 4.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

Review 5.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02

Review 6.  A clinical review of the treatment of catatonia.

Authors:  Pascal Sienaert; Dirk M Dhossche; Davy Vancampfort; Marc De Hert; Gábor Gazdag
Journal:  Front Psychiatry       Date:  2014-12-09       Impact factor: 4.157

Review 7.  Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence.

Authors:  Daniel Felipe Ariza-Salamanca; María Gabriela Corrales-Hernández; María José Pachón-Londoño; Isabella Hernández-Duarte
Journal:  Front Mol Neurosci       Date:  2022-09-29       Impact factor: 6.261
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.